Tag: Resistance to therapy
Search News
BCI researcher receives new Pancreatic Cancer UK Fellowship
20th July 2022
Congratulations to Dr Audrey Lumeau, Postdoctoral Researcher at Barts Cancer Institute, Queen Mary University of London, who has received a Career Foundation Fellowship from the charity Pancreatic Cancer UK to investigate chromosomal instability in pancreatic cancer and its role in therapy resistance.
Read more
In conversation with Professor Marco Gerlinger
20th May 2022
This International Clinical Trials Day, we spoke with Professor Marco Gerlinger. Professor Gerlinger and his team’s laboratory research focuses on understanding and overcoming drug resistance in bowel and gastro-oesophageal cancers, and identifying new and more effective ways to treat these cancers using immunotherapies and combination therapies.
Read more
Rewiring the biology of leukaemia cells to reverse drug resistance
20th April 2022
Researchers from Barts Cancer Institute at Queen Mary University of London have identified a way to reverse resistance to a group of cancer drugs, known as kinase inhibitors, in leukaemia cells. By rewiring the inner workings of the cancer cells, the team was able to prime leukaemia cells for sensitivity to treatment in the laboratory.
Read more
Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more
Overcoming drug resistance in breast cancer
28th October 2021
In recognition of Breast Cancer Awareness Month, we spoke with Dr Ioanna Keklikoglou, Lecturer and Group Leader in the Centre for Tumour Microenvironment at Barts Cancer Institute, Queen Mary University of London. Dr Keklikoglou’s research focuses on understanding the molecular and cellular mechanisms that control resistance to anti-cancer therapies in breast cancer.
Read more
BCI researcher part of team shortlisted for Cancer Grand Challenges awards
23rd June 2021
Dr Benjamin Werner from Barts Cancer Institute, Queen Mary University of London, is part of an international team that has been selected to share its ideas on how to solve one of cancer’s toughest challenges.
Read more